广州市社区人群大肠癌筛查项目成本效益分析

doi:10.3969/j.issn.1006-3110.2020.06.010

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (715 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的对广州市首轮大肠癌筛查项目(2015—2017年)进行成本效益分析。方法本研究资料来源于2015—2017年广州市首轮大肠癌筛查结果。总成本包括筛查总成本、腺瘤直接医疗成本及未来肠镜复查和腺瘤复发治疗成本。总效益包括因筛查而早期检出大肠癌所得效益以及因筛查检出腺瘤及癌前病变避免日后发生癌变所得效益。结果 2015—2017年,广州市首轮大肠癌筛查项目花费总成本为3 928.5万元,总效益为12 329.8万元,净效益为8 401.3万元,效益成本比3.1。如果提高肠镜检查顺应性至30%、40%、50%、60%、70%、80%和90%,大肠癌筛查的净效益和效益成本比均逐渐升高。结论广州市首轮大肠癌筛查项目具有成本效益。肠镜检查参与率越高,成本效益越高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周琴
	李海麟
	谷玉婷
	李燕
	梁颖茹
	刘华章
	冯志强
	林国桢

关键词 ：大肠癌, 筛查, 参与率, 成本效益

Abstract：Objective To analyze the cost-benefit of first-round colorectal cancer screening program (CCSP) in Guangzhou city from 2015 to 2017. Methods The data were collected from the first-round CCSP in Guangzhou city from 2015 to 2017. The total cost included the total cost of screening, the cost of direct medical treatment for adenomas, and the cost of future enteroscopy reexamination and treatment for recurrence of adenomas. The total benefit included the benefit of early detection of colorectal cancer and the benefit of avoiding future cancer due to early detection of adenomas and precancerous lesions. Results From 2015 to 2017, the total cost of the first-round CCSP in Guangzhou city was 39.285 million yuan, the total benefit 123.298 million yuan, the net benefit 84.013 million yuan, and the benefit-cost ratio (BCR) 3.1. If colonoscopycompliancewas improved to 30%, 40%, 50%, 60%, 70%, 80% and 90%, the net benefit and BCR of colon cancer screening would gradually increase. Conclusions The first-round CCSP in Guangzhou city is cost-effective. The higher the participation rate of enteroscopy, the higher the cost-benefit.

Key words： colorectal cancer screening participation rate cost-benefit

收稿日期: 2019-05-22

R735.3

基金资助:广东省自然科学基金-自由申请(2016A030313504);广州市科技计划项目科学研究专项-一般项目(201707010205)

作者简介: 周琴(1982-),女,硕士,副主任医师,研究方向:慢性病预防与控制。

引用本文:

周琴, 李海麟, 谷玉婷, 李燕, 梁颖茹, 刘华章, 冯志强, 林国桢. 广州市社区人群大肠癌筛查项目成本效益分析[J]. 实用预防医学, 2020, 27(6): 674-677. ZHOU Qin, LI Hai-lin, GU Yu-ting, LI Yan, LIANG Ying-ru, LIU Hua-zhang, FENG Zhi-qiang, LIN Guo-zhen. Cost-benefit analysis of colorectal cancer screening program among community population in Guangzhou city. , 2020, 27(6): 674-677.

链接本文:

https://www.syyfyx.com/CN/10.3969/j.issn.1006-3110.2020.06.010 或 https://www.syyfyx.com/CN/Y2020/V27/I6/674

[1] 张玥,石菊芳,黄慧瑶,等.中国人群结直肠癌疾病负担分析[J].中华流行病学杂志,2015,36(7):709-714.
[2] 周琴.广东省广州市2010—2013年结直肠癌疾病负担分析[J].中国肿瘤,2017,26(12):948-952.
[3] 王苗, 霍俊锋,孔军辉. 2002—2014年中国恶性肿瘤死亡城乡差异分析[J]. 实用预防医学,2018, 25(11): 1302-1306.
[4] Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer[J]. N Engl J Med, 2013, 369:1106-1114.
[5] Wilson JMG, Jungner G .Principles and practice of screening for disease[R]. Geneva:WHO, 1968:26-27.
[6] 郑莹,龚杨明,周晓伟,等.从社区实践到公共卫生政策-“上海社区居民大肠癌筛查”项目的规划和实施[J].上海预防医学,2017,29(2):89-113.
[7] 赵丽中,张伟华,马东旺,等.天津市大肠癌筛查初步结果分析[J].中国肿瘤临床,2015,42(15):760-764.
[8] 周琴,沈纪川,刘华章,等.广州市社区人群大肠癌筛查实践研究[J].中国肿瘤,2016,25(6):418-421.
[9] 周琴,李海麟,谷玉婷,等.广州市大肠癌及癌前病变患者疾病经济负担及影响因素分析[J].中国肿瘤,2020,29(1):7-13.
[10] 广州市统计局.统计年鉴2017[EB/OL]. (2017-11-06) [2019-05-05]. http://210.72.4.52/gzStat1/chaxun/njsj.jsp.
[11] 周琴,梁颖茹,李燕,等.广州市人群2015—2017大肠癌筛查成本分析[J].中国肿瘤,2019,28(4):257-263.
[12] Viel JF, Studer JM, Ottignon Y, et al. Predictors of colorectal polyp recurrence after the first polypectomy in private practice settings:a cohort study[J]. PLoS One,2012,7(12):e50990.
[13] Amonkar MM, Hunt TL, Zhou Z, et al. Surveillance patterns and polyp recurrence following diagnosis and excision of colorectal polyps in a medicare population[J]. Cancer Epidemiol Biomarkers Prev,2005,14(2):417-421.
[14] Yamaji Y, Mitsushima T, Ikuma H, et al. Incidence and recurrence rates of colorectal adenomas estimated by annually repeated colonoscopies on asymptomatic Japanese [J]. Gut,2004,53(4):568-572.
[15] Kim JB, Han DS, Lee HL, et al. The recurrence rate of colon polyp after polypectomy and the interval of surveillance colonoscopy:predictors of early development of advanced polyp[J]. Korean J Gastroenterol,2004,44(2):77-83.
[16] Winawer SJ, Zauber AG , O'Brien MJ, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup [J]. N Engl J Med,1993,328(13):901-906.
[17] Menges M, Gartner B, Georg T, et al. Cost-benefit analysis of screening colonoscopy in 40-to 50-year-old first-degree relatives of patients with colorectal cancer[J]. Int J Colorectal Dis,2006,21(6):596-601.
[18] Winawer SJ, Zauber AG, Ho MN, et al. Prevention of cololrectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup[J]. N Engl J Med, 1993,329(27):1977-1981.
[19] 张晓慧,池桂林,许岸高,等.广东惠州地区大肠癌疾病负担研究[J].临床消化病杂志,2011,23(4):220-222.
[20] Murray CJ, Kreuser J, Whang W. Cost-effectiveness analysis and policy choices:investingin health systems [J].Bull World Health Organ,1994,72(4):663-674.
[21] Arafa MA, Farhat KH. Recent diagnostic procedures for colorectal cancer screening: are they cost-effective [J] Arab J Gastroenterol, 2017,18(3):136-139.
[22] Sarfati D, Shaw C, McLeod M, et al. Screening for colorectal cancer: spoiled for choice?[J]. N Z Med J, 2016,129(1440):120-128.
[23] Patel SS, Kilgore ML. Cost effectiveness of colorectal cancer screening strategies[J]. Cancer Control, 2015,22(2):248-258.
[24] Ran T, Cheng CY, Misselwitz B, et al. Cost-effectiveness of colorectal cancer screening strategies-a systematic review[J]. Clin Gastroenterol Hepatol, 2019,17(10):1969-1981.
[25] 谷玉婷,张晋昕,任泽舫,等.广州市越秀区大肠癌筛查成本效益分析[J].中国肿瘤,2015,24(8):657-661.
[26] 陶倩.大肠癌筛查成本效益分析[J].科技致富向导,2013,20:207.
[27] 王冠中,朱菁,顾海雁,等.上海市徐汇区大肠癌筛查成本效益分析[J].上海预防医学,2018,30(7):584-587.
[28] Wu Y, Liang Y, Zhou Q, et al. Effectiveness of short message service intervention to motivate people with positive results in preliminary colorectal cancer screening to undergo colonoscopy: a randomized controlled trial[J]. Cancer, 2019,125(13):2252-2261.